Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON)
Back

Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Nottingham Belfast Wirral Harlow London Manchester Wolverhampton

Medical Conditions

Lung Neoplasms
Small Cell Lung Carcinoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2022 Apr 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

Intervention Arm Group : Lurbinectedin plus Irinotecan;

Intervention Type : DRUG
Intervention Description : Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk

Intervention Arm Group : Lurbinectedin;

Intervention Type : DRUG
Intervention Description : For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk

Intervention Arm Group : Control arm;

Intervention Type : DRUG
Intervention Description : Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk

Intervention Arm Group : Control arm;

Intervention Type : DRUG
Intervention Description : Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk

Intervention Arm Group : Lurbinectedin plus Irinotecan;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Nottingham University Hospitals Nhs Trust
    Nottingham
    NG5 1PB
  • Belfast Health and Social Care Trust
    Belfast
    BT9 7AB
  • Clatterbridge Hospital
    Wirral
    CH63 4JY
  • The Princess Alexandra Hospital
    Harlow
    CM20 1QX
  • Guys and St Thomas NHS Foundation Trust
    London
    SE1 9RT
  • The Christie NHS Foundation Trust
    Manchester
    M20 4BX
  • The Royal Wolverhampton NHS Trust
    Wolverhampton
    WV10 0QP


The study is sponsored by PharmaMar



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05153239
Last updated 29 January 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top